ArticleAnnals of surgical oncology2019
Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.
Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment strategies for elderly patients with locally advanced esophageal cancer: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- A Propensity-Score Matched Analysis to Evaluate Local Treatment Modalities for Esophageal Squamous Cell Carcinoma in Over 80 years on A SEER Database.Clinical interventions in aging · 2025Article
- Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Clinical Impact of the Charlson Comorbidity Index on the Efficacy of Salvage Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer.Internal medicine (Tokyo, Japan) · 2024Article
- Survival Impacts of Impaired Lung Functions and Comorbidities on Elderly Esophageal Cancer Patients.World journal of surgery · 2023Article
- Influence of age as a continuous variable on survival outcomes and treatment options in patients with upper thoracic esophageal carcinoma.Journal of Cancer · 2023Article
- Clinical characteristics and changing trajectories of esophageal cancer and gastric cancer in China from 2010 to 2019: An analysis of a hospital-based database of 24,327 patients.Frontiers in oncology · 2023Article
- Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer-who benefits?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Endoscopic debulking resection with additive chemoradiotherapy: Optimal management of advanced inoperable esophageal squamous cell carcinoma.World journal of gastrointestinal oncology · 2022Article
- External validation of a risk model for survival prediction in older patients with cancer undergoing elective abdominal surgery: a prospective cohort study.American journal of cancer research · 2022Article
- Treatment Patterns and Outcomes of Elderly Patients With Potentially Curable Esophageal Cancer.Frontiers in oncology · 2022Article
- Risk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience.PloS one · 2022Article
- Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer.The Annals of thoracic surgery · 2021Article
- Article
- Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Preoperative Low Vital Capacity Influences Survival After Esophagectomy for Patients with Esophageal Carcinoma.World journal of surgery · 2020Article
- Article
- ASO Author Reflections: Implementation of Age and Co-morbidity in the Treatment Guideline of Patients with Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was designed to assess the impact of age and comorbidity on choice and outcome of definitive chemoradiotherapy (dCRT) or neoadjuvant chemoradiotherapy plus surgery.
methodsIn this population-based study, all patients with potentially curable EC (cT1N+/cT2-3, TX, any cN, cM0) diagnosed in the South East of the Netherlands between 2004 and 2014 were included. Kaplan-Meier method with log-rank tests and multivariable Cox regression analysis were used to compare overall survival (OS).
resultsA total of 702 patients was included. Age ≥ 75 years and multiple comorbidities were associated with a higher probability for dCRT (odds ratio [OR] 8.58; 95% confidence interval [CI] 4.72-15.58; and OR 3.09; 95% CI 1.93-4.93). The strongest associations were found for the combination of hypertension plus diabetes (OR 3.80; 95% CI 1.97-7.32) and the combination of cardiovascular with pulmonary comorbidity (OR 3.18; 95% CI 1.57-6.46). Patients with EC who underwent dCRT had a poorer prognosis than those who underwent nCRT plus surgery, irrespective of age, number, and type of comorbidities. In contrast, for patients with squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, OS was comparable between both groups (hazard ratio [HR] 1.52; 95% CI 0.78-2.97; and HR 0.73; 95% CI 0.13-4.14).
conclusionsHistological tumor type should be acknowledged in treatment choices for patients with esophageal cancer. Neoadjuvant chemoradiotherapy plus surgery should basically be advised as treatment of choice for operable esophageal adenocarcinoma patients. For patients with esophageal squamous cell carcinoma with ≥ 2 comorbidities or age ≥ 75 years, dCRT may be the preferred strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.